Novartis expands radioligand pipeline with $900M Chinese licensing deal

Key points

• Novartis agreed to pay BoomRay up to $900 million for an exclusive global license to an undisclosed preclinical radioligand therapy asset.
• The deal structure includes an upfront payment, milestone payments tied to development and regulatory progress, and royalties on global net sales.
• The specific target, indication, and molecule of the licensed asset have not been disclosed by either company.
• This acquisition follows a January 2026 deal where Novartis licensed a peptide-based radioligand asset from Zonsen PepLib Biotech for $50 million upfront.
• Novartis is expanding its radioligand manufacturing infrastructure, including a new facility in Denton, Texas, and a manufacturing site in China expected to open by late 2026.

Background

Novartis has faced significant scrutiny regarding its acquisition strategy, particularly after the failed $12 billion Avidity Biosciences deal and a phase 3 miss for del-desiran in myotonic dystrophy type 1. These setbacks led to investor pressure for board changes and tighter dealmaking oversight. Despite these challenges, Novartis has continued to invest in radioligand therapies, which have been a core oncology platform since its 2018 acquisitions of Advanced Accelerator Applications and Endocyte. The company recently broke ground on a new radioligand therapy manufacturing site in Denton, Texas, and has invested over CNY 600 million in a Chinese manufacturing facility.

How outlets are covering it

Fierce Biotech highlights the deal as part of Novartis' strategy to combine external innovation with internal R&D capabilities, noting the competitive landscape shift with Telix Pharmaceuticals' acquisition of ITM Isotope Technologies. Pharmaceutical Executive emphasizes the strategic fit of the deal with Novartis' expanding US manufacturing footprint and the common pattern in oncology licensing. AllSci notes the pattern of Novartis licensing early-stage radioligand assets from Chinese biotechs within nine months, while FirstWord Pharma was inaccessible due to a JavaScript challenge. All sources agree on the $900 million total value and the undisclosed nature of the asset, but differ in emphasis on the competitive dynamics and manufacturing infrastructure.

Why it matters

The deal underscores the growing importance of radioligand therapies in oncology and Novartis' strategy to expand its pipeline through external partnerships. It also highlights the increasing trend of large pharmaceutical companies licensing early-stage assets from Chinese biotechs. The deal may help offset recent setbacks in other therapeutic areas and strengthen Novartis' position in the competitive radioligand market.

What to watch

Novartis will take responsibility for advancing the preclinical asset toward clinical development, utilizing its established radioligand therapy infrastructure. The company is expected to continue expanding its radioligand manufacturing capabilities, including the completion of its new US and Chinese facilities. The specific target and indication of the licensed asset may be disclosed in future regulatory filings or press releases.